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 !
 Cardiovascular disease remains the leading cause of death in America impacting 
the lives of millions.  There are many modifiable risk factors that may help in the 
prevention and treatment of cardiovascular disease such as coronary artery disease or 
congestive heart failure. Proper diet and healthy weight management is a crucial factor in 
preventing disease. Dieting is a large component of American living, and the low-
carbohydrate high-protein diet remains the most common form of weight loss. This thesis 
will investigate different types of diets and eating habits that can affect risk of developing 
cardiovascular disease. 
 An apolipoprotein E-deficient mouse model was used to investigate different diets 
and how they may develop cardiovascular disease, more specifically, atherosclerosis in 
the aorta and altered mitochondrial functioning in the heart. The diet of interest for this 
project, was a low-carbohydrate high-protein diet. This diet promotes an environment 
that causes a shift in cellular metabolism due to macronutrient imbalances. Past research 
has yet to address a possible link between low-carbohydrate high-protein diets and 
atherosclerosis and vascular smooth muscle cells, and mitochondrial functioning. This 
thesis contains data that will be of interest to both clinicians and patients, in terms of safe 
dieting and the potential for cardiovascular risk. 
 !
 iv 
Table of Contents 
Chapter I 
Introduction...................................................................................................................................1 
 Theoretical Context………………………………………………………………………..2 
 The Atherosclerotic Process and Pathway………………………………………………....2 
 Pathways Leading to Atherosclerosis……………………………………………………...7 
 Vascular Smooth Muscle Cells & Their Involvement in Lesion Development…………...8 
Structure and Morphology………………………………………………………………....8  
VSMCs: Function and Roles……………………………………………………………....9 
The Diseased Intima: Phenotype Alteration, Migration & Proliferation…………………10 




The role of casein in the development of hypercholesterolemia………………..…….15 
 
Chapter III 
A low-carbohydrate high-protein diet induces vascular smooth muscle cell 
dedifferentiation in an ApoE-/- murine model……………………………………..…….25 
 
Chapter IV 
Altered Mitochondrial Functioning in Apolipoprotein E-Deficient Mice Induced by 
a Low-Carbohydrate High-Protein Diet…………………………………………………...37 
 













List of Figures 
Figure 1: Layers of an artery……………………………………………………….2 
Figure 2: Pathophysiological factors of atherosclerosis…………………………....3 
Figure 3: Schematic illustration of cellular events………………………………....6 
Figure 4: Phenotype shift of vascular smooth muscle cell……………………..…..9 
















































































 Cardiovascular Disease (CVD) is now the second leading cause of death in Canada [1]; 
the main contributor being ischemic heart disease and thus atherosclerosis [2]. With the rise of an 
overweight and obese population, proper weight maintenance is crucial for controlling risk 
factors for CVD and other conditions. Many people resort to exercise and strict dieting for weight 
loss and disease prevention, however not all diets have proven to be safe. Although effective for 
weight loss, the popular low-carbohydrate high-protein diets (LCHP) may be counterproductive 
for CVD prevention in that they may impose damaging effects to blood vessels. The implications 
of a low-carbohydrate high-protein diet will be explored in regards to potential effects on the 
development of atherosclerosis and vascular smooth muscle cell activity. 
 
 
The Atherosclerotic Process and Pathway 
 Atherosclerosis is best described as a chronic 
inflammatory response to a vascular injury, involving 
many inflammatory cells, cytokines and adhesion 
molecules to form an atheroma [3-5]. An atheroma 
involves the deposition of cholesterol and other fatty 
substances as well as necrotic tissue within the intimal 
layer of an artery, rendering the lumen stenotic [6]. The 
artery is composed of three main layers: the intima, 
media, and adventitia (externa) as seen in Figure 1. On 
the innermost layer, the intima, lies a continuous layer 
of cells termed the “endothelium” that essentially separates the blood in the lumen from the rest 
     Figure 1: Layers of an artery [7] 
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of the vessel [8]. The endothelial layer composed of endothelial cells is involved in coagulation, 
inflammatory responses, and vascular tone via phosphorylation of endothelial nitric oxide 
synthase (eNOS) into nitric oxide (NO) [8,9]. The vascular injury present in this disease may be 














          The traditional “response-to-injury” theory states that endothelial stripping absolutely 
caused atherosclerosis [12] however we now understand that there is a spectrum of possible 
insults that can contribute to the morphological changes in endothelium [13]. Endothelial cell 
dysfunction occurs when the normal homeostatic balance of the cell is no longer maintained, 
leading to either impairment in vasorelaxation or up-regulation of adhesiveness on the endothelial 
lining for circulating inflammatory cells [9]. Risk factors such as high amounts of low-density 
lipoprotein cholesterol (LDL-c), hypertension, diabetes, and cigarette smoke can lead to 
Figure 2: Pathophysiological factors that may play a role in atherosclerosis [11] 
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of adhesion molecules such as vascular cell adhesion molecule-1 (VCAM-1),
intercellular adhesion molecule-1 (ICAM-1), E-selectin, and endothelial
leukocyte adhesion molecule is regulated by proinflammatory cytokines such
as tumor necrosis factor-α (TNF-α), interleukin (IL)-1, IL-4, IL-6, and inter-
feron-γ [19]. However, in the presence of endothelial dysfunction, the levels of
these cytokines have been shown to be elevated, which in turn cause more
production of adhesion molecules and thus favor the monocyte recruitment
and adhesion t   endothelium [20]. T e recruited monocytes differentiate
to macrophages in the subendothelial space and further aggravate the develop-
ment of atherosclerosis [21].
Formatio  of F tty Streak
The alteration in endothelial permeability triggers the transmigration of
LDL particles into the intima through the endothelial layer, where it is modi-
fied by oxidative stress to oxidized LDL (Ox-LDL) [22]. Macrophage lipoxy-
genase, myeloperoxidase, and NADPH oxidase are the major sources of
reactive oxygen species production [23]. Oxidation of polyunsaturated fatty
acids within the LDL causes the release of aldehyde and ketones such as
malondialdehyde and 4-hydroxynonenal, which can alter the lysine residues
on apolipoproteins B-100 (apoB-100), the major protein of LDL [24]. The
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endothelial dysfunction; whether it is denudation, the alteration of permeability, or the change of 
cytokine or growth factor secretion [13]. Regardless of the insult ensued; the common factor is 
the damage to the endothelium [13]. 
 Atherosclerosis typically develops in steps that may regress or progress towards an 
unstable atheroma. As abovementioned, disturbance of the endothelial begins the sequence of 
events and the body’s initial reaction is to thicken the vessel wall as a “compensatory 
mechanism” to the damage [13]. A common cause for inflammation in the medium or large sized 
arteries is the state of hypercholesterolemia (14). The arterial inflammatory response begins when 
excess low-density lipoproteins (LDL) infiltrate the intima layer of the artery, and through 
oxidation, the now oxidized LDL (oxLDL) release phospholipids that activate the endothelial 
cells [15,16]. The oxLDL residing in the intima layer is what activates the endothelial cells and 
causes an increased expression of adhesion molecules and inflammatory genes [17]. With 
increased expression of leukocyte adhesion molecules, cells that roll on the surface will adhere to 
the site of activation [18,19]. The two key adhesion molecules that are up-regulated are 
intercellular adhesionmolecule-1 (ICAM-1) and vascular-cell adhesion molecule-1 (VCAM-1) 
[8]. These adhesion molecules will facilitate attachment and transendothelial migration through 
the inter-endothelial junction of leukocytes, such as monocytes and lymphocytes, into the 
subendothelial area [8,20]. Chemokines found in the intima layer will incite the monocytes to 
perform such a migration [14]. Once in the subendothelial region, macrophage colony-
stimulating factor (M-CSF) induces the differentiation of monocytes into macrophages [14]. With 
the help of scavenger receptors located on the macrophage, a broad range of particles, including 
the oxLDL, are “eaten up” by the macrophage, who later transform into foam cells [14,21]. In 
addition to scavenger receptors, toll-like receptors that also bind pathogen-like molecules, but 
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will as well activate the macrophage to produce inflammatory cytokines, proteases, and cytotoxic 
nitrogen and oxygen radical molecules [22]. 
 In a pathological state as such, many pro-inflammatory or pro-oxidative stimuli imposed 
by risk factors can generate reactive oxygen species (ROS) via vascular cells [8]. The production 
of ROS is harmful because they can serve as second-messenger coupling molecules that transmit 
signals to elevate the expression of pro-atherogenic products [8]. A protection against ROS can 
be the antioxidant defense mechanisms. However, when the rate of ROS production exceeds the 
performance of the antioxidant system, the condition of oxidative stress ensues [8]. 
At this stage in the development, fatty streaks or xanthomas are formed due to the large 
lipid core. Most xanthomas can regress by means of lifestyle modifications, and will not fully 
develop into atherosclerotic lesions [23]. However, in the later stages of development, intimal 
hyperplasia occurs in which the arterial wall becomes thickened due to the migration and 
proliferation of vascular smooth muscle cells (VSMC) and the irregular accumulation of 
extracellular matrix [13]. The hyperactivity of the VSMCs will be discussed in greater detail in a 
later section. 
With established lipid deposition and intimal thickening, the plaque can be deemed either 
‘stable’ or ‘unstable’ depending on a variety of factors that may render the plaque vulnerable to 
rupture [24]. Many key players such as T-cells, macrophages, and mast cells [25-27] produce 
molecules that can negatively destabilize a lesion: inflammatory cytokines, proteases, coagulation 
factors, radicals, and vasoactive molecules [14]. ‘Destabilizing’ a lesion implies the destruction 
of collagen in the extracellular matrix, inhibiting the formation of a stable fibrous cap over the 
lesion, or beginning a thrombus formation [28-31]. Destabilization depends entirely on the 
crucial balance between collagen synthesis and collagen breakdown [8]. In one respect, VSMCs 
produce interstitial collagen that offers tensile strength and stability to the maintenance of the 
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fibrous cap [8]. However, due to the presence of T cells, macrophages are induced to produce 
MMPs and cysteine proteases, 2 proteases that play a key role in collagen breakdown [8, 14]. T 
cells may also slow down the collagen production by VSMCs by producing interferon-!, which 
send signals to VSMCs to halt production [8]. The main alarming consequence of atherosclerosis 









Figure 3: Schematic illustration of cellular events in atherosclerosis [32] 
 7 
Pathways Leading to Atherosclerosis 
 It is crucial to acknowledge that atherosclerosis is not solely a ‘lipid-burdened’ disease. 
There are 3 circumstances that may lead to atherosclerosis: inflammation, autoimmunity and 
infection [33]. Many triggers for inflammation occur hand-in-hand with the risk of developing 
atherosclerosis such as oxidized LDL, dyslipidemia, hypertension, diabetes and obesity. These 
conditions may indirectly increase the risk for atherosclerosis by elevating expression of pro-
inflammatory cytokines, chemokines, or adhesion molecules, all of which lead to a pro-
inflammatory atherogenic pathway [33].  
Atherosclerosis has also been speculated to be an infectious disease as some infectious 
agents may generate inflammatory stimuli [34]. Although infectious viruses alone may not be a 
predominant cause, a study showed that patients with coronary artery disease (CAD), had 
elevated levels of antibodies against viruses chlamydia pneumonia, helicobacter pylori, herpes 
simplex, or cytomegalovirus [33,35]. Extravascular infections, such as gingivitis may increase 
inflammatory cytokines in remote atherosclerotic lesions, while intravascular infections may 
provide local inflammatory stimuli [33].  
Many cells of the immune system are involved in the pathologic processes occurring in 
the subendothelial region. Some of these immune cells include macrophages, T-cells, 
autoantibodies, autoantigens, and cytokines (interleukins, tumor-necrosis factor, interferon-!, 
platelet-derived growth factor) [36]. Systemically, the inflammatory response involves acute-
phase reactants serum amyloid-A, fibrinogen, and C-reactive protein [36]. Heat-shock proteins 
(HSPs), proteins found in most species induced by heat shock, have also been shown to promote 




Vascular Smooth Muscle Cells & Their Involvement in Lesion Development 
The VSMC is a highly specialized cell found in mature animals that expresses a unique 
collection of ion channels, signaling molecules, and contractile proteins to perform cell 
contraction [39]. These cells found in blood vessels may proliferate at a very slow rate, and 
express minimal synthetic activity in a healthy environment [39]. 
 
Structure and Morphology 
 The VSMCs essentially act as the bulk of the vessel wall, found mainly in the media layer 
bound together by internal and external elastic lamina [40]. In pathological conditions, VSMCs 
can be found in high numbers in the intimal region, in which they normally represent only a 
minor population. VSMCs will never reside in the adventitia layer, as it is only populated with fat 
cells, fibroblasts, and nerves [40]. These VSMCs have been suggested to express two main 
phenotypes: contractile and synthetic [40, 41]. Smooth muscle cells exhibiting a contractile 
phenotype are found in the media layer and are common in healthy, differentiated arteries 
containing many microfilament bundles [42]. These contractile cells are spindle-shaped, as seen 
in figure 4, and contain copious amounts of contractile fibers such as actin and myosin [40]. 
Upon migration to the intimal layer during atherosclerosis, the VSMCs experience a phenotype 
switch to the synthetic, which is typical of a diseased artery [42]. These dedifferentiated synthetic 
cells are more rhomboid-shaped and contain cytoplasm that have a prevalence of rough 
















VSMCs: Function and Roles 
 VSMCs share two primary functions in the arterial wall: contractility and structure [40]. 
In arteries and veins, the main structural components are the VSMCs and the extracellular matrix, 
composed of collagen and elastin [13,40]. VSMCs maintain a contractile role due to the large 
expression of proteins smooth muscle (SM) !-actin isoform, myosin heavy chain (MHC), 
smoothelin, alpha tropomyosin, calponin, caldesmon, myosin regulatory light chain 2, 
intermediary filaments vimentin and desmin, as well as many other proteins [40,44,45]. With the 
support of the array of proteins, the cells can maintain tone and play a major part in 
vasoconstriction following physiological or pharmacological stimuli [13]. In other words, 
following a pulse wave, the layer of VSMCs can act as an elastic reservoir for energy because it 
in turn regulates the blood flow following nervous or humoural stimulation [40]. The phenotype 
of the cells in the media layer is best described as “contractile”, however as we will discuss in the 
next section, this phenotype is altered once intimal hyperplasia occurs [46]. VSMCs are unique in 
that they are not terminally differentiated, which is classic of cardiac or skeletal muscle. They can 
experience plasticity that allows phenotype adaptations in response to cellular environmental 
stimuli [47]. 
Figure 4: Phenotype plasticity of the VSMCs. The cell on the right represents a 
contractile, differentiated VSMC, while the cell on the left represents a 
dedifferentiated synthetic cell responding to vascular injury [43]. !
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The Diseased Intima: Phenotype Alteration, Migration & Proliferation 
 The proliferation of smooth muscle cells is a response-to-injury and a necessary process 
to occur at the onset of inflammation [48]. There are three main phases in the response that cause 
movement of VSMCs and intimal hyperplasia. During the initial onset, replication of VSMCs 
occurs, typically stimulated by the release of basic fibroblast growth factor (bFGF) from the dead 
and damaged cells [40]. Once having multiplied, the smooth muscle cells will migrate towards 
the intima from the internal elastic lamina of the medial layer. During the migration of the 
VSMCs, a change of phenotype occurs from contractile to fibroblast-like synthetic phenotype 
[47]. Many molecules mediate this travelling action; however platelet-derived growth factor 
(PDGF) plays a crucial role and has been debated to be mitogenic for VSMCs [40]. Once having 
reached the intimal region, the third phase entails proliferation of the cells and secretion of 
extracellular matrix with the ability to form a stable “fibrous cap” between the lipid lesion and 
arterial lumen [49].   
The proliferatory phase for the VSMCs will occur under the influence of an assortment of 
growth factors and cytokines, and only upon completion, will the extracellular matrix be released 
and accumulated in abnormally large amounts [23]. Factors that can act as chemotactic agents for 
the smooth muscle cells are; PDGF, acidic fibroblast growth factor (aFGF), bFGF, !-thrombin, 
and insulin-like growth factor 1 (IGF-1) [13,50-53]. These compounds are termed ‘chemotactic’ 
because they will affect the normal activity of the VSMCs in the media and favor changes 
towards migration and proliferation of the cells [13]. In contrast, there are substances produced 
that inhibit VSMC proliferation and intimal growth in response to the vascular stimuli: heparin, 
TGF-", and nitric oxide (NO) [54]. In effect, these chemotactic growth factors along with 
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infiltrating leukocytes and adhesion molecules allow for a positive feedback loop that continue 
the vicious cycle of VSMC hyperactivity and increased intimal thickening [13,55]. 
Aside from the increased VSMC activity towards the intima, the extracellular matrix 
plays a perilous role in plaque development. The synthetic VSMCs in the intima are different 
from the contractile VSMCs in that they secrete proteins of the extracellular matrix, such as 
collagen I and II [23]. The components of the extracellular matrix offer tensile strength for the 
arterial wall; due to the VSMC’s production of collagen fibers (types I, III, V), small 
proteoglycans, and the elastic membranes [56,23]. In an atherosclerotic plaque, there is 
exaggerated matrix deposition that severely narrows the vessel lumen [23]. Moreover, the 
distribution of collagen and elastin is distinct, since the intimal extracellular matrix exhibits much 
more collagen and much less elastin than does the medial extracellular matrix [23]. It has recently 
been speculated that perhaps macrophages may also be able to produce some components of the 
extracellular matrix by means of secretion of TGF- ! [23]. With excessive extracellular matrix, 
the fibrous cap atheroma will begin to form. The atheroma entails the accumulation of partially 
necrotic foam cells from the earlier inflammatory phase, which is separated from the vessel 















Low-Carbohydrate Diets and Cellular Metabolism  
 Under normal homeostatic conditions, protein provides a small amount of 2-5% of the 
body’s energy requirements; predominant contributions for energy originate from carbohydrates 
(CHO) and fats [57]. In situations where CHO availability is limited, the body must compensate 
by utilizing its stores of glycogen in the liver and muscle to maintain normal blood glucose levels 
and supply the cells with glucose [58]. In diabetic scenarios where glucose is not taken up into 
the cells, or states of glycogen depletion, which usually begin at 48 hours of total CHO 
restriction, cellular fuel adaptations occur and a shift towards the use of fatty acids transpires; fat 
mobilization > fat oxidation [57,58]. Fat oxidation begins to dominate once glycogen stores are 
exhausted and gluconeogenesis does not suffice [58]. With the same energy sources being using 
Figure 5: Schematic of the exaggerated matrix deposition and VSMC activity, 
resulting in plaque development [13]. 
!
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but in different proportions, the fuel source shifts from being “glucocentric” to “adipocentric” 
[59]. 
 When triglycerides are forced to be broken into fatty acids and glycerol for energy use, a 
process called !-oxidation occurs in the mitochondria to convert fatty acids into a readily useful 
form [60]. The fatty acids are converted into acetyl-CoA and can enter the Krebs Cycle in the 
same fashion as glucose. In conditions lacking CHO and fat for energy, protein catabolism offers 
an important source of energy in a few ways. Before any amino acids (AA) can be oxidized, 
removal of the amino group must occur. In one instance, the detached amino group can get 
transferred and given to another AA (ketoacid), to form a new AA [57]. This process is called 
transamination. Otherwise, oxidative deamination can occur when the amino group may be 
removed and become free ammonia (NH3) [61]. Nevertheless, when the amino group is removed, 
a carbon skeleton is remaining and may become oxidized or converted to form different 























 Dieting trends and use of supplementation is practiced widely in North America for 
various reason, many of which focus on weight loss or disease prevention. The goal of this thesis 
is to better understand how manipulating macronutrient distribution in the diet can have profound 
effects on a cellular level both beneficial and harmful. Animal source protein, such as casein or 
whey is commonly used for protein supplementation with the goal of gaining muscle mass. 
Casein protein is frequently used for custom-made animal diets for research purposes. Animal 
proteins are of interest to researchers due to their potential hypercholesterolemic effect in humans 
and animals. This matter will be investigated in depth in the published review paper to follow.  
 Another common use of dieting is a low-carbohydrate high-protein diet, generally 
referred to as the “Atkin’s diet”. This carbohydrate-eliminating method of weight loss has yet to 
be studied in regards to cardiovascular health, more specifically vascular smooth muscle cells in 
atherosclerosis and mitochondria functioning in congestive heart failure. Reduction of 
carbohydrates has a direct implication in the normal cellular metabolism, whereby a shift from a 
carbohydrate energy source to a fat energy source occurs. These projects aim to assess whether 
this shift can affect the vascular smooth muscle cells and their role in development in 
atherosclerosis in the thoracic aorta, more specifically their phenotype shift from contractile to 
synthetic phenotype. As well, the mitochondrial respiration will be assessed in the cardiac tissue 
whether they function better in a lipid-rich environment. Information from this thesis can provide 
ample information to health care professionals and individuals engaging in dieting practices, to 
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Abstract Atherosclerosis remains the leading cause of
severe cardiovascular complications such as cardio- and
cerebrovascular events. Given that prevention and early
intervention play important roles in the reduction of
cardiovascular complications associated with athero-
sclerosis, it is critical to better understand how to target
the modifiable risk factors, such as diet, in order to best
minimize their contributions to the development of the
disease. Studies have shown that various dietary sources
of protein can affect blood lipid levels, a modifiable risk
factor for atherosclerosis, either positively or negatively.
This clearly highlights that not all proteins are “created
equal.” For example, consumption of diets high in either
animal- or vegetable-based sources of protein have re-
sulted in varied and inconsistent effects on blood cho-
lesterol levels, often depending on the amino acid com-
position of the protein and the species investigated.
Careful consideration of the source of dietary protein
may play an important role in the prevention of athero-
sclerosis and subsequent cardiovascular complications.
Given the recent focus on high protein diets, an empha-
sis on controlled studies in the area is warranted. The
goal of this review is to present the current state of the
literature that examines the effects of casein, a common-
ly utilized animal-based protein, on blood cholesterol
levels and the varying effects noted in both animals and
humans.
Keywords Casein protein . Hypercholesterolemia . Soy
protein . Lipoprotein . Cardiovascular disease
Cholesterol and the development of atherosclerosis
Atherosclerosis lies at the root of many serious cardio-
vascular complications such as myocardial infarction,
stroke, gangrene, intermittent claudication, and limb
amputation [39]. The initiation of the atherosclerotic
process depends mainly on the state and function of
the endothelial layer, which represents the demarcation
between the vessel wall and the blood [15]. Endothelial
dysfunction is characterized by two aspects: a reduction
of the bioavailability of nitric oxide, which leads to
impaired vasoreactivity, and the activation of the endo-
thelial cells [7, 51]. Taken together, these features induce
a pro-inflammatory, proliferative, and pro-coagulatory
state, all of which contribute to the progression of ath-
erogenesis [1]. Factors associated with endothelial dys-
function include smoking, oxidative stress, diabetes,
metabolic dysfunction, obesity, hypercholesterolemia,
and hypertension [20] (Fig. 1).
High-density lipoproteins (HDL) are considered to
be a negative risk factor for the development of cardio-
vascular disease and have been casually referred to as
“good” cholesterol. The cardioprotective effects of HDL
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are due to its role in reverse cholesterol transport (RCT),
a key process that regulates cholesterol clearance from
the systemic circulation. The purpose of RCT is the
removal of excess (free) cholesterol from peripheral
cells and reuptake by the liver for eventual bile salt
synthesis and excretion [8]. In the early stages of ath-
erosclerosis, a higher than normal concentration of cir-
culating low-density lipoproteins (LDL) results in their
penetration into the subendothelial layer of the blood
vessel. LDL, transported by apolipoprotein B (ApoB)
into the vascular wall, becomes biochemically modified
and, subsequently, triggers an inflammatory response
[21]. There are three histological features of the unstable
atheroma: (1) the large lipid core which is present when
the abovementioned RCT is incapable of regulating
blood cholesterol levels, (2) the abundance of inflam-
matory cells, and (3) a thin fibrous cap [17, 22]. The
atheroma is not only a collection of cholesterol, waste,
and fibrotic tissue but is also a lesion composed of
endothelial and smooth muscle cells with infiltrating
leukocytes and other inflammatory cells [32]. Essential-
ly, the initial endothelial dysfunction leads to the fatty
streak formation and, ultimately, fibrous cap formation
[39].
The risk of developing atherosclerosis and conse-
quent ischemic heart disease increases with the presence
of pro-atherogenic substances such as intermediate den-
sity lipoproteins (IDL), low-density lipoproteins (LDL),
and very low-density lipoproteins (VLDL) [33]. Evi-
dence in the literature has suggested that certain proteins
appear to exert a greater effect on blood cholesterol
levels than others [50]. Given that the recent trend
towards high protein diets in the pursuit of weight loss
and reduction of chronic disease risk, it remains imper-
ative to fully appreciate the associations between certain
protein types and the potential for increased cardiovas-
cular disease risk. This increased risk may occur despite
successful weight loss. The goal of this review paper is
to examine whether casein, a dietary source of protein,
has an effect on blood cholesterol and whether it can be
considered a positive risk factor for the development of
atherosclerosis.
What is casein and does it have a role
in the atherosclerotic process?
Over the last five decades, there has been a steady
interest in the abilities of certain proteins to promote
either a pro- or anti-atherogenic effect. In particular,
casein has often been included in studies as an animal
source of protein [50]. Milk products contain two main
protein components: whey and casein. Whey protein
represents approximately 18 to 20 % of mammalian
milk protein, while casein represents the remaining
80–82 % [4]. Casein is regarded as one of the most
Fig. 1 Schematic view of the arterial wall and the steps in ather-
oma formation. Risk factors such as a biochemical imbalance
(high LDL) trigger an endothelial activation beyond the normal
noxious stimuli. LDL enters the subendothelial layer and become
oxidized to allow attraction of monocytes, cytokines, and other
inflammatory cells to support the inflammatory process
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nutritive milk proteins, as it contains all common amino
acids and is rich in essential amino acids (EAA) [45].
Purified casein is produced from skim milk by a pro-
cessing technique where the protein is separated from
the whey, dried, and then resolubilized [9]. Isolated milk
casein forms micelle complexes when dispersed in the
water phase of milk. The micelle structures have five
different subunits of the casein subtype: α-casein, α-2
casein, β-casein, κ-casein, and γ-casein. Common
among these five structures are the calcium-phosphate
bonds that hold them together and that they all contain
salt and water [9].
The primary difference between casein, whey pro-
tein, and other high-quality proteins is the rate of digest-
ibility. Casein is considered to be a slow-digesting pro-
tein because it curdles or gels in the stomach, thus
delaying release in the intestines. This results in a grad-
ual but steady rise in blood amino acid concentration
following ingestion [9]. Since the blood amino acid
concentrations are kept relatively low, it slows but ex-
tends the rate of protein synthesis [16]. Casein also
demonstrates anti-catabolic properties, which simulta-
neously inhibits protein breakdown [4, 6]. In situations
where weight loss is desired, the anti-catabolic proper-
ties of casein result in it being the preferred source of
protein for hypocaloric diets [5]. In light of these char-
acteristics, casein is attractive for many weight loss
programs that include high protein intake.
As early as the 1970s and 1980s, animal studies
reported that casein increased serum cholesterol levels,
thus playing a role in the development of atherosclero-
sis. Previously, it was believed that cardiovascular dis-
ease and atherosclerosis were a result of the amount of
fat in the diet and, in particular, the cholesterol and
saturated fats. In light of results seen in animal studies,
a high casein diet may also be considered a risk factor in
the development of atherosclerotic plaque. Casein-
mediated hypercholesterolemia has been shown to de-
velop independently of exogenous cholesterol and sat-
urated fat consumption [28]. Studies have been per-
formed in order to compare lipid profiles upon adher-
ence to diets that vary in amount of cholesterol,
cholesterol-free semi-purified diets, and various protein
sources. Early studies have shown that soy protein, a
source of vegetable protein, appears to play a protective
role in the vasculature and reduces the concentration of
total cholesterol and LDL, contrary to the detrimental
effects of casein [10]. A negative association between
soy protein intake and the development of coronary
heart disease and nonfatal myocardial infarctions was
also shown in a group of middle-aged and older Chinese
women [52], although these protective effects of soy are
not detected in all studies [24]. The association between
animal-based protein and cardiovascular disease is also
supported by a meta-analysis of five prospective studies
that compared mortality in vegetarians and non-vegetar-
ians. This analysis showed that subjects who consumed
animal protein had a 24 % higher mortality from ische-
mic heart disease, even after controlling for potential
confounding factors such as age, sex, smoking status,
alcohol, habitual exercise, education, and body mass
index [29]. Given the potential detrimental effects of
casein and other animal-based proteins in the develop-
ment of vascular disease, as suggested in studies such as
these, it is important to consider dietary protein source
when recommending high protein diets rather than con-
sidering all proteins equal.
The effects of casein in the animal model
Research conducted in male New Zealand white rabbits
by Huff and colleagues clearly demonstrated that chang-
es in body weight, plasma cholesterol, triglyceride
levels, as well as liver cholesterol occurred upon varying
the dietary protein source (i.e., either animal or plant
protein) [26]. The diet used in the Huff study was termed
a “low-fat semi-purified diet”, consisting of either 27 %
casein or soy isolate, along with 60 % dextrose, 5 %
celluflour, 4 % salt mix, 3 %molasses, and 1 % corn oil.
The 16 animals were divided into 2 groups: 8 received a
diet rich in casein and 8 received a diet rich in soy
protein isolate. This low-fat semi-purified diet was giv-
en to both groups for 10 months, resulting in signifi-
cantly lower levels of mean plasma cholesterol in the
soy isolate group as compared to the casein semi-
purified group. After 10 months, the casein-fed animals
ended up with higher mean triglyceride levels, higher
liver cholesterol (Table 1), and developed atherosclerot-
ic lesions, particularly in the aortic arch region. Despite
the negative effects on plasma lipids and cholesterol,
casein-fed animals gained less weight than the soy-fed
animals (2.9 and 3.3 kg, respectively).
Plasma VLDL, LDL, and IDL levels were all signif-
icantly higher in the casein-fed versus the soy-fed ani-
mals (Table 2). Huff and colleagues concluded that this
hypercholesterolemic state must be the result of choles-
terol that is endogenously produced by the liver or
Effects of casein on blood lipid profile 1023
intestine in response to the manipulation of dietary
protein source [26]. This significant rise in IDL, the
main transporter of cholesterol, has been observed under
similar conditions since although the underlying cause
remains speculative [44].
In the Huff study, it is interesting that both the casein
and soy diets lacked exogenous cholesterol and were
low in saturated fats. From these, it is evident that the
source of protein directly affects the distribution pattern
and concentration of cholesterol being transported in the
blood [26]. The amino acid composition of the protein is
as important as the protein source [11]. It is known that
amino acids vary in their effects on serum cholesterol
concentrations, as well as further variations when
ingested as proteins [11]. Illustrating this concept, the
amino acids lysine and methionine contribute to the
development of hypercholesterolemia, whereas arginine
is able to counteract this effect [30, 31]. The essential
amino acids found in casein have been hypothesized to
be responsible for the observed increase of total choles-
terol and LDL [11]. By replacing casein with isolated
soy protein, which has a different amino acid composi-
tion, the increases in total and LDL cholesterol content
in the serum associated with casein can be avoided [3].
Terpstra and colleagues reported similar results, but
their data also demonstrated the dose effect of casein fed
to Zucker strain rats [46]. Their study included six
groups of animals fed with either a commercial diet with
no cholesterol, a commercial diet with 1.2 % cholester-
ol, or four types of semi-purified cholesterol enriched
diets (20 % casein, 50 % casein, 20 % soybean, or 50 %
soybean (g/100 g of feed)). The results revealed a more
prominent hypercholesterolemic effect occurring in di-
ets with a higher percentage of casein. The same effect
was observed in rabbits [25, 46], as well as in pigeons
[34, 35].
Evidence in the literature supports the notion that the
casein-mediated cholesterol increases may be biphasic
in nature: extremely low and extremely high amounts of
casein in the diet appear to have the greatest impact on
blood cholesterol levels [27, 40]. Increases in cholester-
ol were most apparent with either diets containing rela-
tively small amounts (5 %) or large amounts (40 to
60 %) of casein. Diets consisting of moderate amounts
of casein (i.e., 20 %) appeared to produce the smallest
effects [19]. Gender also appears to play a role: Female
rats were more predisposed to developing hypercholes-
terolemia in response to casein ingestion [47]. This
observation had also been previously reported by Filios
and colleagues [19] with blood cholesterol levels dou-
bling in magnitude in female versus male rats.
Research conducted by Hermus and colleagues fo-
cused on demonstrating the different combinations of
protein with gelatin on serum cholesterol levels and
body weight gain in rabbits [23]. The team set up four
experimental groups: (1) semi-purified diet containing
strictly casein as the protein source; (2) casein and
gelatin; (3) casein, gelatin, and fish protein; and (4)
casein, gelatin, fish protein, and soy protein. After
58 weeks of diet adherence, the group fed the diet
consisting of casein only demonstrated a growth-
retarding effect compared to the other groups who
achieved normal growth. Additionally, the casein group
Table 1 The condition of the rabbits following the observance of
a casein- or soy-rich diet. Cholesterol and triglyceride contents in
the plasma and liver were all significantly elevated, excluding the





Mean plasma cholesterola (mg/dl) 247±12 66±3b
Liver cholesterol (mg/g wet wt) 6.6±1 3.3±0.2b
Mean plasma triglyceridea (mg/dl) 95±4 58±3b
Liver triglyceride (mg/g wet wt) 7.0±0.7 6.6±0.3
Lipid profile in rabbits fed either casein or soy protein diet for
10 months. Results are expressed as a mean ± SE for 8 rabbits in
each dietary group
a The overall mean ± SE for the entire 10-month period
b Significantly different from the casein-fed group P<0.01 from
Student’s t test
Table 2 The varying distribution of plasma cholesterol that de-
veloped among the four lipoprotein classes: VLDL, IDL, LDL,
and HDL, as well as the total plasma concentration. Differences
with both diet groups in all lipoprotein classes are significant,
excluding the HDL (adapted from [26] with permission)
Density class Casein (mg/dl) Soy protein (mg/dl)
VLDL d<1.006 76±6 11±3a
IDL 1.006<d>1.019 132±14 25±6a
LDL 1.019<d>1.063 46±6 10±2a
HDL 1.063<d>1.21 19±4 12±3
Total plasma concentration 275±25 58±6a
Plasma cholesterol distribution among lipoprotein classes. Results
are expressed as mean ± SE for 6 rabbits in each dietary group
a Significantly different from the casein-fed rabbits (P<0.01) from
Student’s t test
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also achieved a hypercholesterolemic state that was
unseen in the other three experimental groups. This
study demonstrated that the addition of alternate protein
sources to the diet was able to blunt the hypercholester-
olemic effects of casein.
Overall, it is understood that the atherosclerotic pro-
cess can be initiated by hypercholesterolemia, with se-
rum total cholesterol and lipoproteins being well-
established risk factors for the disease [21]. Although
elevated concentrations of serum cholesterol contribute
to the development of fatty streaks, this is not the sole
reason for disease susceptibility [28]. Other known risk
factors, such as family history, obesity, chronic hyper-
glycemia, and physical and/or biochemical injuries,
have also been implicated [21, 28]. To fully appreciate
the origins and mechanisms involved in the progression
of atherosclerosis, what has been learned from studies
involving possible dietary sources of cholesterol must
also be considered. When certain animals are fed with a
casein-rich diet, there is a higher correlation with lipo-
philic plaques and high serum cholesterol content than a
diet consisting of plant protein [28]. The lipoprotein
density concentration is also altered, depending on
whether a plant or animal protein source is considered
[37]. Theories suggest that soybean protein contain sa-
ponins, which are protective against hypercholesterol-
emia [42]. It is also thought that dietary fiber increases
absorption of bile acids in the intestine. This will result
in loss of bile acid through fecal excretion which will be
compensated by stimulation of hepatic conversion of
cholesterol into bile acids [41]. The main question is
how casein protein causes an elevation in cholesterol,
such that the protein source is as detrimental as the
source of fat [26]. What provokes this mechanism to
increase cholesterol to such a level as to induce athero-
genic plaque?
Many speculations and theories have been put forth
over the past 30 years as to how and why casein inges-
tion raises cholesterol levels and why certain species are
more susceptible to the effects of casein. The activity
and concentration of enzyme alkaline phosphatase play
an important role since it has the potential to dephos-
phorylate casein and prevent accumulation of
phosphopeptides [36]. In 1988, Van Der Meer and col-
leagues conducted studies that involved feeding both
rabbits and rats a similar diet that included elevated
casein content in order to investigate intestinal absorp-
tion and bile acid excretion. They reported that casein
induces a hypercholesterolemic effect in rabbits due to
low intestinal phosphatase activity and with a high
glycine conjugation of bile acids, whereas in the rat,
where little effect of casein was noted, the conjugation
of bile acids occurs primarily via other amino acids,
such as taurine [48].
Another potential factor that may contribute to the
effects of casein is the LDL receptors. It has been
reported that animals fed casein-enriched diet had a
downregulation of hepatic LDL receptors preceded by
an increase in plasma cholesterol [12]. Other studies
have also shown that casein stimulates LDL ApoB
synthesis, therefore increasing the circulating LDL [11].
What effect does casein have in a human model?
Contrary to the observations seen in animals, the major-
ity of intervention studies that have investigated the
effects of plant and animal protein on serum cholesterol
levels in humans have reported inconsistent effects. In
1983, Sacks and colleagues tested whether dairy protein
(casein) or soy protein would have an effect on plasma
cholesterol in 13 strict vegetarians. The study design
consisted of a 1-week pre-intervention period, during
which, baseline measurements such as body weight,
cholesterol profile, triglycerides, and VLDL-c/TG ratio
were measured. Following the baseline period, all 13
subjects were split into groups that followed two phases:
a diet enriched in casein for 20 days and then soy for
20 days or vice versa. Results yielded no significant
changes in LDL or protective HDL cholesterol from
baseline. As well, there was no difference of lipid profile
or lipoproteins in the soy and casein groups during their
40-day intervention [43].
Another study conducted by Van Raaij and col-
leagues looked at similar aspects, but in healthy non-
vegetarian subjects eating a “western” simulated diet.
All 69 participants began by eating a casein-soy or
“cassoy” diet for a control period of 10 days in order
to establish baseline measurements for the remainder of
the experimental design. In this cassoy diet, 65 % of the
protein content was a 2:1 mixture of casein and soy,
respectively. Following the 10-day control period, indi-
viduals were divided into three groups for 28 days:
maintenance cassoy diet, casein diet, or soy diet. Inter-
estingly, there were barely any changes seen between
the experimental casein and soy groups in regard to total
cholesterol. Subjects adhering to the casein-enriched
diet did not demonstrate any significant changes in
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lipoprotein fractions. On the other hand, the soy group
demonstrated improvements in the LDL and HDL con-
centrations as compared to the casein group, and the
reductions in LDL were also significant within the soy
group from their baseline measurements [49]. The im-
provements in LDL-c and HDL-c were also seen in
another study with participants eating a cholesterol-
enriched casein or soy diet [38]. VLDL concentrations
remained unchanged in both study groups.
Crouse and colleagues conducted a similar study
with healthy individuals having elevated LDL concen-
trations between 3.62 and 5.17 mmol/L. Subjects main-
tained a casein-rich diet or a soy-rich diet with varying
amounts of isoflavones for 9 weeks. Following this
dietary intervention, LDL-c and total cholesterol
lowered significantly from baseline in individuals in
the soy group, with a dose-dependent relationship be-
tween cholesterol improvements and isoflavone
amount. There was no significant improvement in
HDL-c or TG concentration between the groups [14],
suggesting that casein supplementation is not an effec-
tive intervention for individuals with pre-existing high
cholesterol.
From these studies performed on humans, the results
suggest that casein protein may not have such a pro-
nounced effect on cholesterol levels as seen in certain
animal models, such as rabbits. The studies share mixed
results and conclusions. A soy diet would be more
beneficial for lowering cholesterol levels in hypercho-
lesterolemic patients since casein-enriched diets demon-
strate few advantages in lowering LDL-c or TG. In
healthy subjects, on the other hand, it seems as though
casein and soy diets lack influence on cholesterol levels
[43]. However, it should be pointed out that, in order to
better mimic the study design in animals, the human
experiments would need to be conducted for longer
periods of time and/or administered at earlier periods
in their lives [49]. The important point here is to con-
sider whether the lack of effect is indeed a phenomenon
in the human model or whether it is due to limitations in
study design. Further work is needed in order to objec-
tively determine the safety of diets high in casein.
Clinical implications of a high casein diet
Meal replacements (MR) containing elevated amounts
of plant or animal protein have proven successful in
promoting weight loss in obese patients. In a
randomized controlled trial by Anderson and colleagues
[2], patients consuming a MR with high casein for
16 weeks had a tendency towards more weight loss
and greater fat loss than individuals on high soy diets.
Although associated with only modest weight loss, the
individuals consuming soy MR showed promising im-
provements in their cardiovascular risk profile (i.e.,
LDL, TC, visceral fat, and systolic blood pressure).
The period following weight loss is crucial to success-
fully sustain weight reduction, and for this, high casein
diets have been found to be useful [13].
Attention must also be drawn to the popular use of
protein supplementation following exercise training.
Postprandial protein synthesis has been studied, and
the data indicates that amino acids dictate future protein
synthesis, breakdown, and oxidation [6]. Protein shakes
of whey and casein are frequently used to maintain and
increase muscle mass, hence protein synthesis or anab-
olism following exercise. As compared to whey protein,
ingestion of casein protein in a meal or drink may only
induce a small increase in protein synthesis, but is
associated with a substantial decrease in protein break-
down [6]. These physiological processes are possible
due to the retarded increase in plasma AA concentra-
tions. Without the pronounced hyperaminoacidemic
peak associated with whey, casein offers a “longer last-
ing” rise in AA levels and sustains protein breakdown
inhibition. Casein supplementation, compared to whey,
has been shown to improve body composition resulting
in decreased percent body fat; an increase of lean mass;
and greater muscle strength in legs, chest, and shoulders
[18]. These effects are most likely due to casein’s anti-
catabolic property. Depending on individual aims or
motives, athletes may opt for casein as their choice of
protein supplementation for the aforementioned
reasons.
Conclusion
Casein is not only naturally present in foods containing
dairy such as milks and cheeses but is also extensively
utilized in its purified form as a powdered protein sup-
plement. For decades, saturated fats, and cholesterol
have been deemed responsible for the development of
cardiovascular disease and conditions such as athero-
sclerosis and the “clogging of arteries.” Studies have
also found that casein protein is just as aversive as fats
for some animal species. Casein can have a negative
1026 O.H. Koury et al.
impact on the serum cholesterol concentration and raise
it to levels that pose a severe danger to the lipid profile.
There have been speculations that casein is responsible
for the disruption of bile acid binding in the small
intestine, leaving elevated levels of free bile acids to
be re-absorbed. It is key to clearly understand whether
hypercholesterolemia is enough to induce atherosclero-
sis and simulate endothelial dysfunction and to what
extent does it raise cholesterol and cause atherosclerosis.
Another important aspect that would require further
investigation is the possibility that humans may mani-
fest the same hypercholesterolemic dangers of casein if
given for longer periods of time comparable to animal
studies. Although healthy humans are assumed to be
less sensitive to dietary modifications than animals,
there may be changes noted if the human studies would
parallel animal studies in terms of time periods and
administration [49]. Would a diet low in fats but high
in animal protein be harmful to individuals and pose
cardiovascular risks? The potential dangers of casein
should serve as a red flag for dieters, trainers, physi-
cians, or nutritionists alike, especially when considered
for populations who may already be considered at risk
for cardiovascular complications. In regard to supple-
mentation, patients in a rehabilitation setting due to
conditions such as cancer cachexia or sarcopenia may
also be administered large doses of soy, whey, or casein.
Also of concern are people who exercise train and
consume exceptionally high concentrations of
whey or casein protein supplementation in order
to increase protein synthesis and muscle mass.
Understanding the implications of a high casein
protein diet is vital in order to assess the health
status and long-term lipid profile of an individual
adhering to such a diet.
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Obesity has been associated with a host of adverse 
health conditions, such as insulin resistance, systemic 
inflammation and cardiovascular disease risk factors 
[1, 2]. Due to the deleterious effects of obesity on both 
society and the individual, the search for an efficient 
and safe means of weight loss remains a priority. Diets 
that are rich in protein and/or fat, with limited 
carbohydrates (i.e.: the Zone, Dr. Atkins) have earned 
attention due to their obvious potential for weight 
reduction. Despite their apparent “success”, it remains 




































these methods of weight loss. Recent data obtained in a 
murine model, highlights the possibility that not all 
diets are created “equal” and that the traditional serum 
risk markers used to assess weight loss programs may 
not capture the full picture. In the study by Foo et al., 
(2009), Apolipoprotein E-knockout (ApoE-/-) mice 
given a low-carbohydrate high-protein (LCHP) diet 
(12% carbohydrate, 43% fat, 45% protein and 0.15% 
cholesterol) developed more aortic atherosclerotic 
lesions and impaired ability to generate new vessels in 
response to tissue ischemia when compared to both a 
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control group (regular chow diet of 65% carbohydrate, 
15% fat and 20% protein) and, more interestingly, mice 
put on a representation of a western-type diet (43% 
carbohydrate, 42% fat, 15% protein) [3]. Although the 
data presented in the Foo et al. study is interesting in 
terms of the presence of atherosclerosis in the aorta, the 
link that they present between the low 
carbohydrate/high protein diet and the formation of 
lesions primarily rests on the evaluation of endothelial 
progenitor cells. These observations, however, do not 
take into consideration the stages in the development of 
atherosclerosis itself. Early atherosclerotic progression 
consists primarily of the infiltration of fat into the 
vascular wall and formation of fatty streaks and is 
reversible through dietary modifications, 
pharmacological interventions and exercise [4].  
The following stages of atherosclerosis involve 
the development of the lipid core and stabilization of a 
fibrous cap, involving largely vascular smooth muscle 
cells (VSMCs) [5]. Differentiated VSMCs are highly 
specialized units, located in the media layer of arteries. 
Their primary function is to contract and relax, 
consequently controlling blood pressure and blood flow 
distribution [6-10]. In a healthy adult vessel, the 
contractile phenotype is characterized by markers such 
as smooth muscle (SM) !-actin, calponin, SM22-!, 
SM-myosin heavy chain, h-caldesmon [9]. Unique to 
VSMCs is their remarkable plasticity as they, unlike 
cardiomyocytes or skeletal muscle cells, are not 
terminally differentiated [9,11] and can thus modify 
their phenotype according to physiological 
provocations [11]. This shift from contractile to 
synthetic state serves great importance during vascular 
development and pathology as it allows for malleability 
and thus reversible adaptations [6, 10-12]. Following 
vascular injury, contractile VSMCs go through a 
transient modification of phenotype, which involves a 
reduced expression of contractile genes [10]. This 
plasticity seems to be necessary and may confer a 
survival advantage since it provides means for the 
smooth muscle to respond to altered conditions in its 
surroundings. The dedifferentiation of the VSMCs 
leads to migration and proliferation to the intimal layer, 
followed by the formation of connective tissue matrix 
that accumulates lipids and both free and esterified 
cholesterol [13]. At the point where vascular smooth 
muscle cells actually dedifferentiate and migrate into 
the vessel wall, the atherosclerotic lesions are 
considered no longer reversible and may present a 
serious concern in terms of cardiovascular risk [14]. 
However, the solid formation of extracellular matrix by 
VSMCs is also thought to serve as a protective 
component in plaque stabilization [13, 15] 
subsequently preventing rupture [16]. The situation is 
exacerbated by the continuous accumulation of 
macrophages that ingest lipids and become foam cells 
[17, 18]. At this stage, the response is thought to be 
chronic and the lesion progresses to a more advanced 
stage.  
Foo et al as well as many other studies have 
looked at the effects of a low-carbohydrate diet in 
terms of insulin resistance, hypertension, ketosis, 
however, to date nothing has been produced about the 
VSMC phenotype switching [19-24]. The goal of this 
study was to determine whether the altered 
physiological environments induced by a low-





Apolipoprotein E knockout (ApoE-/-) mice 
were obtained from Jackson Laboratories (Bar Harbor, 
Maine, USA) and used for breeding. The resulting 
litters were weaned and separated based on sex at 21-
28 days. The males were housed individually and 
randomly assigned to one of three diets for 6 weeks: 
control (CON), western (WD), and low-carbohydrate 
high-protein (LCHP) diet. All procedures were 
approved by the Animal Ethics Committee of 
Concordia University (protocol ID: #30000259) and 
were conducted in accordance with guidelines of the 
Canadian Council on Animal Care. 
 
Diet Specifications 
All 3 animal diets were iso-caloric. Table 1 
displays the diet specifications in terms of percentage 
of caloric intake from fat, carbohydrates, and protein. 
The CON diet, 5075 Charles River Autoclavable 
Rodent Diet, reflects a healthy, standard macronutrient 
distribution. The WD, obtained from Harlan 
Laboratories (TD.110229) replicates a high-fat high-
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carbohydrate ‘American’ diet, consisting of 42% from 
fat, 42% from CHO, and 16% from protein. The LCHP 
diet, obtained from Harlan Laboratories (TD.04524) 
simulates an Atkin’s diet used for weight loss and 
contains 43% from fat, 11% CHO, and 46% protein. 
Both WD and LCHP diets are modifications of 
TD.88137 (Harlan Laboratories), used for studies of 
atherosclerosis, and contain comparable amounts of 




 Control Western LCHP  
Carbohydrates 63% 42.2% 11% 
Fats 14% 42.1% 43.2% 




Oil Red O Staining  
 Oil Red O (ORO) staining, quantifying the 
lipid deposits within the vessel, was performed 
according to Nunnari et al. [25] on fresh tissue from 
the thoracic aorta. A 3% stock solution was prepared 
(10 ml isopropanol, 0.3g Oil Red O Powder from 
Sigma-Aldrich), as well as a working stain consisting 
of stock solution and water (3:2 parts respectively) 
filtered through a Whatman No. 1 Filter. The aortas 
were cleaned of adventitial fat and then soaked in the 
working stain for 30min, rinsed in distilled water, 
cleaned again of excess adventitial fat, and split 
longitudinally to measure for area. Samples were then 
individually placed in chloroform: methanol (1:1) 
solution for 2 min to extract the stain before the 




 The thoracic aorta was removed from the 
sacrificed animal cleaned of fat and connective tissue, 
and stored at -80°C. The tissue was then 
pulverized/homogenized using liquid nitrogen with 
~70µl lysis buffer containing (in mM) 250 NaCl, 50 
HEPES (pH 7.5), 10% glycerol, 1% triton X-100, 1.5 
MgCl2 1 EGTA, 10 Na4P2O7 NaF, 800 µM Na3VO4. 
After 1 hour on ice, the cell slurry was centrifuged at 
13,000 rpm for 10 min, and the supernatant was 
collected. 10µl of lysate was mixed with 2µl DTT and 
2µl sample buffer and loaded on a 10% acrylamide-
SDS gel followed by a transfer onto a 0.45µm 
nitrocellulose membrane (162-0115 Bio-Rad) in 10mM 
sodium tetraborate buffer. Ponceau staining was done 
as loading control before the membranes were blocked 
in 3% bovine serum albumin (BSA) in 0.1% Tween 20 
in Tris-buffered saline (TBS) (10mM Tris-HCl, pH 7.5, 
150 mm NaCl) for 1 hour at room temperature. This 
was followed by overnight incubation 4°C with Abcam 
primary antibodies: !-actin ab5694 (1:2000), calponin 
ab46794 (1:2000), TRPC1 ab88182 (1:2000). The 
membranes were then washed, and incubated with 
secondary antibodies: TRPC1 and calponin ab6721 
(1:15000), !-actin ab6728 (1:15000). Membranes were 
exposed with ECL chemiluminescence and developed 
bands were analyzed with Image J Software.  
 
Isometric Force 
 Vessels were dissected free of surrounding 
tissue and sliced into sections ~3mm in length. 
Sectioned vessels were mounted onto the Radnoti wire 
myograph working chamber with a 25µm Tungsten 
wire. Once securely mounted, the vessels were 
stretched to identical basal tonus in a Ca2+-free Kreb’s 
solution containing (in mM) 117.9 NaCl, 4.7 KCl, 1.2 
MgCl2, 25 NaHCO3, 1.2 NaH2PO4, 0.0027 EDTA, 0.1 
ascorbic acid, 11 glucose. Once stable, 6 ml of HEPES 
buffered Kreb’s solution containing (in mM) 135.5 
NaCl, 5.9 KCl, 1.2 MgCl2, 11.6 glucose, 11.6 HEPES, 
pH 7.4 (NaOH) was added. When a stable baseline was 
attained the solution was changed to High K+ (HK) for 
approx. 6 min to induce maximal membrane 
depolarization and thus highest contraction. This 
process was repeated for a second High K+ contraction 
after sufficient relaxation. Following the second HK 
contraction and relaxation, endothelin-1 (ET-1) (Sigma 
Aldrich E7764) was added to the chamber giving final 
concentration of 10nM for approx. 5 min to generate a 
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Statistical Analysis 
Quantitative data are mean ± SEM. Statistical analysis 
was determined with 2-tailed Student’s t-test or single-
factor ANOVA. p < 0.05 was considered significant. n 
represents the sample number. In the figures presented, 




Weekly Weight Gain Shows Peaks only in First 
week 
Weekly weight was recorded over the 6 weeks of the 
study as shown in Figure 1. The first week on the 
respective diets translated to a significant difference in 
weight gain, with the WD showing a 58% increase, 
while the LCHP showed a 37% increase, and the CON 
a 39% increase (p< 0.01, n=11) from their baseline 
weight. However in the following weeks, there was no 
notable difference in weight gain amongst the three 
groups. The largest peak and difference in weight was 
therefore only seen in the beginning. 
 
Lipid   Accumulation is Quantified  
To evaluate whether there was a meaningful 
accumulation of lipid in the thoracic aorta that would 
lead to an atherosclerotic lesion, an Oil Red O staining 
protocol was conducted. Recordings in Figure 2 show 
that despite trends, there was no significant difference 
of lipid deposition within the tissue in the WD and 
LCHP as compared to the CON (73.5%± 12.5 and 












Contractile Markers Show a Down-Regulation 
Paralleling Phenotype shift in VSMCs 
To investigate how the various diets affected the 
expression of contractile markers, thoracic aortas were 
homogenized and western blot analysis revealed altered 
protein expression. As seen in Figure 3, the !-actin 
expression was significantly down regulated in the WD 
and LCHP as compared to the CON (89.6%± 4.7 and 
79.5%± 7.6 respectively, p<0.05, n=9). Similarly, there 
was a significant down-regulation of calponin in the 
WD and LCHP as compared to the CON (87.7%± 6.1 
and 71.4%± 6.1 respectively, p< 0.01, n=8). Synthetic 
phenotype would be marked by the significant 
increased expression of TRPC-1 channels in the WD 
and LCHP, also seen in Figure 3 (141.1%± 23.9 and 
154.3%± 13.7 respectively, p< 0.05, n=8). There was 
no significant difference in any of the 3 markers 
between WD and LCHP diets, despite consistent trends 































Figure 1. Weekly weight increases show peaks in weight 
gain in first two weeks upon weaning, as well as a trend of 
lowest weight gain in the LCHP group, an expected 
outcome of this diet. 
Figure 2: ORO staining protocol revealed a non-
significant trend in lipid deposition, relative to the control 
(73.5% ±12.5 and 87.2%± 15.5, p=0.39, n=6) 
















                           
 
 
VSMC Dedifferentiation did not Translate to a 
Deficit in Functional Capacity  
To further examine the loss of contractile phenotype in 
the cell, the contractile ability was investigated. For 
this, 2-3mm aortic segments were suspended in a 
Radnoti wire myograph working chamber. There was a 
negligible difference between the maximal force 
generated by the 3 groups (CON, WD, and LCHP) 
following depolarization of the cell membrane by 
High-K saline solution (100%± 7.2, 106.6%± 15.8, 
106.3%± 9.0, respectively, p>0.05, n=12). 
Furthermore, we investigated the reactivity of the 
VSMCs to ET-1, and the induced contraction relative 
to the HK tension generated was once again 
comparable between the 3 groups CON, WD, and 
LCHP (42.2%±7.0, 42.7% ± 3.4, 42.7% ± 3.2 









    
A pilot study was performed by Foo and 
colleagues using the same 3 diets as in this study, 
showing an increased percentage of atheroma in the 
aorta of animals on the LCHP diet compared to the WD 
and CON [3]. This finding raised the following 
question: if significantly higher amounts of 
atherosclerotic plaque develop in LCHP animals 
compared to the CON and WD, the activity of the 

























































Figure 3. Immunoblotting shows a significant trend of 
dedifferentiation occurring by a decreased expression of !-
actin compared to CON (89.6%± 4.7 and 79.5%± 7.6,p= 
0.047, n= 9), decreased expression of calponin compared to 
CON (87.7%± 6.1 and 71.4%± 6.1, p= 0.0088, n= 8), and 
increased expression of TRPC1 compared to CON (141.1%± 
23.9 and 154.3%± 13.7, p= 0.033, n=8).  













     calponin 
TRPC1 
Figure 5. There is no difference in force generated 
following HK membrane depolarization in the WD and 
LCHP diet, compared to CON (106.6% ± 15.8, 106.3%± 9, 
± 0.018 respectively, p= 0.92, n=12).  
Error bars represent SEM. 
Figure 6. There is negligible difference in the 
vasoreactivity to ET-1 compared to the HK, between the 3 
groups (42.2%±7.0, 42.7% ± 3.4, 42.7% ± 3.2 
respectively, p=0.99, n=12) 
Error bars represent SEM. 
Figure 4: Representative protein gels of immunoblotting  
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The main finding from this study was the 
evident shift of phenotype from contractile to synthetic 
within the VSMCs. Evaluating the state of the mature 
vessel depends on the relative presence of a variety of 
contractile apparatus proteins such as SM !-actin [26-
28] and calponin [29-31], amongst others. It is evident 
that !-actin plays a vital role in cell contraction and is 
required for force-generating capacity of the VSMC  
[9, 32, 33] In murine aortic SM, 94% of the SM-actin is 
found in the !-type [34]. Similarly !-actin comprises 
>25% of the total protein in differentiated VSMCs 
proving to be the single most abundant protein in these 
matured cells [34-36]. It is well accepted that this 
predominant form SM !-actin, is greatly reduced 
following endothelial injury, and could represent as 
low as only 10% of the total SM-actin protein, formerly 
94% [26, 37]. Our data demonstrated an approximate 
20% reduction of !-actin in the LCHP from the control 
group, and 10% reduction in the WD. In cell 
differentiation, SM !-actin gene is activated early in 
embryonic development, and expressed early in the SM 
lineage [36, 38-42].  
Another traditional contractile marker is 
calponin, first discovered in 1986 by Takahashi and 
colleagues [43]. Calponin, a calcium regulatory 
protein, is involved in regulation of SM contraction 
[10]. Calponin interacts with actin and tropomyosin in 
a Ca2+-independent manner, and calmodulin in a Ca2+-
dependent manner [43, 44]. The amounts of calponin 
were decreased by approximately 30% in the LCHP 
and around 12% in the WD relative to the control 
group, conceptualizing the idea of loss of contractile 
property. Calponin is known to be expressed as an 
intermediate marker in the differentiation and 
dedifferentiation of SMC [29]. 
In addition to contractile proteins to mark an 
altered phenotype, other changes such as membrane 
properties, receptor population, and Ca2+ control might 
ensue prior to phenotype modulation [45]. Ca2+ 
handling and manipulation can have a gross impact on 
resultant cellular contraction, wherein addition of 
extracellular Ca2+ channels can have a profound 
proliferative effect [46, 47]. T-type calcium channels, 
more specifically the TRPC-1 type [48, 49], have been 
linked to store-operated Ca2+ entry (SOCE), which has 
been found to be up-regulated in proliferating SMCs of 
the pulmonary artery [50].  Kumar and colleagues 
established that calcium channel TRPC-1 is commonly 
increased in blood vessels as a compensatory protective 
response following vascular injury [51]. This fact 
parallels the shift to synthetic previously described, 
since there was a 54% increase of TRPC1 in the LCHP 
and 41% increase in the WD compared to the CON 
group.  
Since we observed a modulation of contractile 
proteins in the VSMCs, we questioned whether this 
alteration was provoked by an increase in lipid or some 
other endogenous factor. Although atherosclerosis is 
now understood to be more of an inflammatory disease, 
rather than a lipid-burdened disease [52], we 
nevertheless wanted to assess whether an excess of 
lipid may have played a role. An ORO staining 
protocol was used to quantify the concentration of lipid 
residing in the thoracic aorta. Interestingly enough, 
there was less lipid content in the WD and LCHP 
compared to the CON, however these trends were not 
significant.  
Following evidence of a phenotype shift, the 
functional capacity of the cell was examined by means 
of wire myography. Whereby the pressure myography 
is favorable for small vessels with significant 
vasoreactivity, the wire myograph is a sensitive method 
preferred for larger vessels and records the tension 
produced under isometric conditions [53]. The aorta 
was sectioned and tested using High-K+ saline and 
endothelin-1 (ET-1) solution, predicted to demonstrate 
a decrease in tension or force produced. ET-1 is a 
potent vasoconstrictor and pro-inflammatory peptide 
[54]. Contrary to our expected outcome, the data 
revealed no difference in either case of induced 
contraction from the High-K solution or 
vasoconstrictor ET-1. The explanation for this 
observation may be two-fold.  From one perspective, 
the 6-week length of study may have been premature to 
witness an impairment of vascular contractility. 
Contractile proteins !-actin and calponin are early and 
intermediate markers of dedifferentiation respectively, 
and only provide grounds to confirm events occurring 
at a certain point in time: early to intermediate 
dedifferentiation [29, 38]. Perhaps, functional capacity 
is only affected during late dedifferentiation. Lesions 
containing foam cells and VSMCs are typically seen at 
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8-10 weeks old in an ApoE -/- mouse given normal 
chow [55, 56] however, we noted a change in VSMC 
after 6 weeks of diet (approximately 9 weeks old). 
Fibrous plaques tend to appear at 15-20 weeks of age 
[55, 56].  It may have been an option to extend the 6 
weeks, and see if the increased time translated to a 
subsequent loss in contractile response. On the other 
hand, it could be speculated that the thoracic aorta may 
never exhibit impressive contraction, as it is not 
physiologically responsible for maintenance of 
vascular tone and high vasoreactivity.  Nonetheless, 
this is not a sound argument since there are studies that 
investigate vascular contractility in the aorta [36, 57]. 
Complete loss in contractile response following 
depolarization with KCl is possible, and has been 
shown using control and !-actin null mice [36], 
displaying a fundamental dysfunction in the contractile 
system with alteration in SM !-actin genes. 
Data from this study show that a particular diet 
low in carbohydrates and high in protein, offers an 
imbalanced environment that favors a synthetic 
phenotype in VSMCs. Macronutrient composition is 
altered in a LCHP diet, consequently affecting the fuel 
sources and cellular metabolism. Although the same 
energy sources are utilized, the majority of the energy 
is now derived from fatty acids and ketones, hence an 
‘adipocentric’ energy source as opposed to a 
‘glucocentric’ source [58]. LCHP diets are frequently 
used for rapid and efficient weight loss, and this is 
conceptualized by the fact that LCHP animals did not 
gain as much weight as the WD (37% and 58%, 
respectively) in the beginning weeks, as seen in Figure 
1.  In a LCHP diet, approximately 70% of caloric 
requirements come from fatty acids via dietary fat or 
lipolysis, 20% come from ketone bodies acetoacetate 
and "-hydroxybutyrate, and 10% from glucose via 
gluconeogenesis or glycogenolysis [59]. This 
adaptation is of no surprise; it is thought that a 
substrate or by-product of using such energy sources 
plays an indirect role in mediating phenotype shift in 
VSMCs.  
Platelet-derived growth factor-BB (PDGF-BB) 
is well documented as being responsible for some 
phenotype regulation, since it is a chemotactic agent 
meaning, a molecule that favors migration and 
proliferation [60-63]. Although there is a link with 
PDGF and suppressed marker genes, another very 
influential factor is the gene known for maintenance of 
pluripotent embryonic stem cells: Kruppel-like Factor 4 
(KLF4) [64]. Not typically expressed in adult 
mesenchymal cells [65], KLF4 becomes re-expressed 
and plays a role in mediating SMC phenotype 
switching in vivo [60, 66], since it strongly represses 
expression of SMC genes [60]. Following vascular 
injury, ApoE -/- mice on a WD showed increased 
expression of KLF4 [67, 68] and this abundance of 
KLF4 is accompanied by an inhibition of expression of 
known SMC marker genes [69]. KLF4 also has the 
ability to inhibit the increase of SMC differentiation 
mediated by TGF-" [14]. Taken together, this provides 
reason to speculate whether KLF4 can serve as a 
plausible endogenous factor indirectly involved in the 
VSMC activity through growth factors however, this 
theory lies beyond the scope of this study. 
 
Conclusion  
This study aimed to assess the effects of a low-
carbohydrate high-protein diet on the role of vascular 
smooth muscle cells in atherosclerosis. Prior to our 
study, a possible link between VSMC phenotype and 
LCHP diets had never been made. This study 
emphasized how such a topic does indeed merit further 
enquiry, as there is a clear dedifferentiation occurring 
in VSMCs of ApoE -/- mice on a LCHP diet, 
potentially providing intriguing or relevant data for 
clinicians and patients both interested in this type of 
diet. !
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The recent rise in obesity has been associated with a 
number of adverse health effects such as heart disease, 
certain types of cancer, type-2 diabetes mellitus, and 
respiratory complications [1]. In efforts to reduce 
associated health risks, overweight and obese patients 
have been advised to maintain a healthy BMI. One of 
the most efficient means of weight loss is through 
dieting, more specifically a low-carbohydrate high-
protein diet (LCHP). This diet has gained much 
popularity with the American public [2], and advocates  




































loss without adverse long-term effects [3]. 
Macronutrient composition is altered in a LCHP diet, 
drastically affecting the cellular metabolism. Although 
the same energy sources are utilized, majority of the 
energy is now derived from fatty acids and ketones due 
to the extreme reduction of carbohydrate. This is shifts 
metabolism from a ‘glucocentric’ source to an 
‘adipocentric’ energy source [4]. In LCHP metabolism, 
70% of caloric requirements come from fatty acids via 
dietary fat or lipolysis, 20% come from ketone bodies 
acetoacetate and !-hydroxybutyrate, and 10% from 
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for 6 weeks. Heart tissue was used for immunoblotting, and high-resolution respirometry (HRR) to quantify 
mitochondrial complexes and measure oxidative phosphorylation (OXPHOS) capacity. Our results indicate increased 
expression of all five mitochondrial complexes in the LCHP group compared to the control. Furthermore, HRR 
revealed increased efficiency of substrate utilization implying improved mitochondrial respiration. These findings 
correlate well with the understanding that cardiomyocytes prefer lipid as a fuel source, and the shift in metabolism 
caused by a LCHP diet provides such a favourable environment. 
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glucose via gluconeogenesis or glycogenolysis [5]. 
LCHP diets have been studied extensively in the past 
decades regarding weight loss, lipid markers, insulin 
sensitivity, hypertension, and endothelial dysfunction 
[6-11]. However, no study has addressed a possible 
link with LCHP diets and heart failure due to cardiac 
mitochondrial dysfunction. 
 Despite a general decrease in the number of 
deaths from cardiovascular disease (CVD) in the 
United States, congestive heart failure (CHF) remains 
as prevalent today as it was two decades ago [12]. 
Although very broadly defined, CHF can be best 
described as a multifactorial syndrome that renders the 
myocardium unable to pump blood efficiently to 
sustain demand [13]. Oxidative stress is now 
understood to be a key factor in heart failure, and a 
main reason for oxidative stress is the imbalance and 
negative impact of reactive oxygen species (ROS) 
produced by the mitochondria [14-18]. In recent years, 
studies have linked characteristics of heart failure to 
defective mitochondrial energetics and abnormal 
substrate metabolism [19- 21]. There is significant 
evidence showing mitochondrial dysfunction not only 
in cardiomyocytes, but also skeletal muscle of heart 
failure patients [22]. Aside from mitochondrial 
dysfunction, other problems that may contribute to the 
noticeable energetic defects are the number of 
mitochondria, substrate of choice, or oxidative capacity 
[23]. These facts imply that preserving cardiac 
mitochondrial functioning can become a future 
therapeutic aim for CHF [24-26]. 
Mitochondria are potentially significant 
sources of ROS especially when damaged (i.e. by long-
term FA accumulation,) where they exhibit decreased 
oxidative based energy and thus less fuel for cells [27]. 
This is a central concern since the mitochondrion is the 
organelle in which energy (ATP) production and 
cellular respiration occur [28, 29]. Considering the 
maintenance of ATP drives all cellular processes, this 
process is imperative for a high-level workload organ 
such as the heart due to its high-energy demands [25, 
30-33]. The capacity of the mitochondria relies heavily 
on substrate availability, notably lipids and 
carbohydrates. These substrates contribute to energy 
metabolism depending on their utilization through !-
oxidation and the Kreb’s cycle. !-oxidation produces 
acetyl-CoA from FAs that enters the Kreb’s cycle, 
generating electrons that are successively transported to 
the electron transport system (ETS) by NADH and 
FADH2 to amplify ATP production [34]. The Kreb’s 
cycle is the focal common aerobic metabolic pathway 
for carbohydrates, lipids and proteins [35]. Acetyl-CoA 
oxidation by this cycle is responsible for two thirds of 
the sum of ATP production and oxygen consumption 
[36].  
Despite glucose and FAs both being oxidized 
in the mitochondria to ATP production in the 
cardiomyocytes, the latter is the preferred substrate 
(generating 70% of total ATP) [37-39]. Therefore, the 
uptake of FA from the plasma is vital for cardiac 
viability [21, 37- 40]. Furthermore, lipids have also 
been deemed necessary for the maintenance and re-
initiation involved with the pure beating of heart cells, 
further highlighting their significance [41]. The heart 
has limited substrate storage capacity, thus the uptake 
of nutrients needs to be finely balanced since the 
underlying pathways have to respond both 
appropriately and competently to the continuous flux in 
energy demand and substrate availability [25]. Under 
normal conditions the mitochondria maintain a fine 
equilibrium between glucose and FAs, however, during 
physiological stress, the mitochondria shifts towards an 
increased carbohydrate metabolism. This shift adds 
stress to the heart and shunts the lipids into non-
oxidative pathways creating more ROS than energy 
[42]. The activity of respiratory complex I in the 
mitochondria is especially prone to the effects of 
oxidative damage [43]. The same detrimental 
phenomenon occurs when there is a reduced oxygen 
supply as a result of the occlusion of the coronary 
vessels, a major cause of cardiovascular distress [44].  
 The mitochondria are an important health 
research target considering their role in generating 
cellular energy, by means of oxidative phosphorylation, 
a process affected by uptake of cholesterol and lipids 
from the plasma. The subsequently altered role of 
mitochondria may potentially be implicated in the 
pathophysiology of heart failure [45] and overall 
cardiovascular health. The apolipoprotein E deficient 
(ApoE-/-) murine model is a well-established model as 
it allows for the investigation of atherosclerosis due to 
its susceptibility to develop lesions rapidly, and 
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similarly to humans  [46-48]. ApoE is a 34 kDa 
glycoprotein made in the liver and brain, responsible 
for lipoprotein metabolism [48]. It helps to clear 
circulating cholesterol by mediating the binding of 
ApoE-containing lipoproteins and LDL receptors [49- 
52]. 
This study examined whether ApoE-/- mice 
exhibit altered cardiac mitochondrial oxidative capacity 
when exposed to a low-carbohydrate high-protein 
environment. We quantified cardiac mitochondrial 
consumption in a 6-week old ApoE-/- murine model in 
comparison to age-matched controls. The results 
determined if alterations in energy metabolism had 
occurred by examining the oxidative capacity of the 
mitochondrial respiratory complexes. We hypothesized 
that the mitochondria from the ApoE-/- cardiac tissue 
would experience increased respiratory function and 




Apolipoprotein E knockout (ApoE-/-) mice 
were obtained from Jackson Laboratories (Bar Harbor, 
Maine, USA) and used for breeding. The resulting 
litters were weaned and separated based on sex at 21-
28 days. Only the tissue from male mice was used for 
the purpose of this study. The males were housed 
individually in a thermo-neutral environment (22ºC), 
on a 12:12 h photoperiod, and randomly assigned to 
either a control diet (CON) or a low-carbohydrate high-
protein (LCHP) diet for 6 weeks. Both groups of mice 
had access to water and their respective diets ad 
libitum. All procedures were approved by the Animal 
Ethics Committee of Concordia University (protocol 
ID: #30000259) and were conducted in accordance 




Both CON and LCHP animal diets were iso-
caloric. Table 1 displays the diet specifications in terms 
of percentage of caloric intake from fat, carbohydrates 
(CHO) and protein. The CON diet, 5075 Charles River 
Autoclavable Rodent Diet, reflects a healthy, standard 
macronutrient distribution. Whereas, the LCHP diet, 
obtained from Harlan Laboratories (TD.04524) 
simulates an Atkin’s diet used for weight loss and 
contains 43% from fat, 11% CHO, and 46% protein. 
The LCHP diet is a modification of TD.88137 (Harlan 
Laboratories), used for studies on atherosclerosis.  
 
Experimental protocol 
The beating heart was removed immediately 
after euthanasia with CO2 according to the approved 
animal protocol and split into two different portions. 
One portion was snap frozen in liquid nitrogen, and 
stored at -80ºC for biochemical analysis; the other 
portion (the apex) was placed in an ice cold relaxing 
buffer (BIOPS) and used immediately to measure 
mitochondrial respiration. The BIOPS contains (in 
mM): CaK2EGTA 2.77, K2EGTA 7.23, Na2ATP 5.77, 
MgCl2!6H2O 6.56, Taurine 20, Na2Phosphocreatine 15, 
Imidazole 20 mM, Dithiothreitol 0.5, MES 50, pH 7.1 
 
Preparation of permeabilized cardiac fibers 
The apex was dissected for preparation of 
permeabilized myofibers. This was done by gentle 
dissection during which the fiber bundles were 
separated using sharp forceps. The fibers were then 
incubated in 3 ml BIOPS buffer containing 50 "g/ml 
saponin for 30 minutes and subsequently washed in 
ice-cold buffer (MiR05) for 2 x 10 min. MiR05 
contains (mM): EGTA 0.5, MgCl2!6H2O 3.0, K-
lactonionate 60, Taurine 20, KH2PO4 10, HEPES 20, 
Sucrose 110, BSA 1g/l, pH 7.1. 
 
Mitochondrial respiratory measurements 
Measurements of oxygen consumption were 
performed in MiR05 at 37ºC using a polarographic 
oxygen sensor (Oxygraph-2k, Oroboros Instruments, 
Innsbruck, Austria). Approximately 2.0 to 2.5 mg of 
muscle tissue (wet weight) was place in either chamber 
in a cross-sectional design. O2 flux was resolved by 
DatLab and all experiments were carried out in 
hyperoxygenated levels to avoid O2 diffusion 
limitations. A sequential substrate addition protocol 
was used to allow functional dissection of the electron 
transport system: state 2 respiration (absence of 
adenylates) was assessed by addition of malate (2 mM) 
and octanoyl carnitine (1.5 mM), by adding ADP (5 
mM) we could reach state 3 respiration for complex I. 
This was followed by addition of glutamate (10 mM) 
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and succinate (10 mM) achieving maximal coupled 
state 3 respiration with parallel electron input to 
complex I and II. Oligomycin (2 µg/ml) was then 
added to block complex V and thereafter antimycin A 
(2.5 µM) to inhibit complex III. Finally ascorbate (2 
mM) and TMPD (500 µM) were added to evaluate 
Complex IV respiration.  These mitochondrial 
respiratory measurements were recorded for both the 




There were 6 different protocols, some of 
which were variations of one another, used to test for 
the presence of uncoupling as we wanted to ensure that 
the results obtained would not be from a potential 
uncoupling effect. A portion of the apex tissue 
mentioned previously was also studied using high-
resolution respirometry (Oxygraph-2k, Oroboros 
Instruments, Innsbruck, Austria) to test for uncoupling, 
running simultaneously along side the mitochondrial 
respiratory experiments. The first protocol began with 
the addition of oligomycin (2 µg/ml) followed by 
succinate (10 mM), then FCCP step titrations (1 
µl/step) and finally antimycin A (2.5 µM). The second 
protocol was the same as the first except GDP (10mM) 
was added in between the addition of succinate and 
FCCP. Therefore, uncoupling protein 1 (UCP1)-
mediated uncoupling could be studied through the 
titrations of oligomycin, GDP and antimycin A. The 
third protocol consisted of the sequential addition of 
succinate (10 mM), ADP (5 mM) and then glutamate 
(10 mM) and malate (2 mM) simultaneously. The 
fourth protocol included the addition of malate (2 mM), 
octanoyl carnitine (1.5 mM), ADP (5 mM), glutamate 
(10 mM), oligomycin (2 µg/ml) and then finally 
multiple additions of GDP (10mM). The fifth protocol 
began with the addition of malate (2 mM) then 
octanoyl carnitine (1.5 mM), glutamate (10 mM), 
oligomycin (2 µg/ml) and again multiple additions of 
GDP (10mM). The sixth an final protocol consisted of 
adding malate (2 mM) then octanoyl carnitine (1.5 
mM), oligomycin (2 µg/ml) and then multiple additions 
of GDP (10mM). 
 
Protein Extraction, Immunoblotting, and 
Immunofluorescence 
Tissue from the cross-section excised from 
right above the apex was pulverized/homogenized 
using liquid nitrogen with ~150µl lysis buffer 
containing (in mM) 250 NaCl, 50 HEPES (pH 7.5), 
10% glycerol, 1% triton X-100, 1.5 MgCl2 1 EGTA, 10 
Na4P2O7  NaF, 800 µM Na3VO4. After 1 h on ice the 
cell slurry was centrifuged at 13,000 rpm for 10 min, 
and the supernatant was collected. 10µl of lysate was 
mixed with 2µl DTT and 2µl sample buffer and loaded 
on a 12.5% acrylamide-SDS gel followed by a transfer 
onto a 0.45µm nitrocellulose membrane (162-0115 
Bio-Rad) in 10mM sodium tetraborate buffer. Ponceau 
staining was done as loading control before the 
membranes were blocked in 3% bovine serum albumin 
(BSA) in 0.1% Tween in Tris-buffered saline  (TBS) 
(10 mm Tris-HCl, pH 7.5, 150 mm NaCl) for 1 hour at 
room temperature, followed by overnight incubation at 
4°C with primary antibody, total OXPHOS rodent 
antibody cocktail (1:2000, MS604 MitoSciences).  The 
membranes were washed, and incubated with 
secondary antibody (1:15000, anti-mouse, ab6728 
Abcam). Membranes were exposed with ECL 
chemiluminescence (Immun-Star Chemiluminescent; 
1705070; Bio-Rad) and developed bands were 
analyzed with Image J Software. 
 
Statistical Analysis 
Summarized data are presented as means ± standard 
error of the mean (SEM) for immunoblotting, and 
standard estimate.  Statistical comparisons were done 
using a two-tailed Student’s t-test. n represents the 
sample number. For all statistical evaluations, In the 




Relative Expression of Complexes I-V 
Immunoblotting revealed an increase in all five 
complexes in the LCHP diet, normalized to the CON. 
These trends can be seen in Figure 1 however, only 
CIV showed a statistically significant difference in 
expression (CON: 100% ±5.7, LCHP: 122% ±4.8, p< 
0.05 n= 6). Therefore, the only significant change in 
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protein expression was in CIV when running samples 











Mitochondrial respiration  
We examined oxygen consumption rates of saponin-
permeabilized fibres to determine oxidative capacities 
of mitochondria in the cardiac muscles in situ along 
with control of the respiratory activity by ADP, the 
principal regulator. Mitochondrial leak, estimated as 
antimycin A flux rates subtracted from oligomycin flux 
rates, indicated a significant increase in the LCHP 
group as compared to the control group as seen in 
Figure 3 (52.4 ± 16.1 and 102.2 ± 12.1pmol/s/mg, 
respectively, p<0.03). There was also a significant 
difference between these two groups in terms of 
substrate control ratio for succinate (GM3/GMS3) 
(0.62 ± 0.08 and 0.44 ± 0.02, respectively, p<0.05) as 
illustrated in Figure 4. Neither the respiratory control 
ratio (RCR, state 3 over state 4 respiration so succinate 
divided by oligomycin respiration) (2.2 ± 0.8 and 3.0 ± 
0.6 ) or the acceptor control ratio (ACR, maximal, ADP 
stimulated respiration divided by basal, ADP restricted 
respiration in other words ADP divided by malate 
respiration) (8.5 ± 1.4 and 12.0 ± 1.4), respectively, a 
ratio representing the degree of coupling between 
oxidation and phosphorylation showed any significant 
differences as seen in Figures 5 and 6. Therefore there 
was no indication of a likely more efficient oxidation 
of substrates, nor a significant change within the 
OXPHOS process. Lipid OXPHOS capacity shown in 
Figure 7 shows the absence of a significant difference 
in the lipid coupling control ratio (L/P) between these 
two same groups (0.33 ± 0.04 and 0.26 ± 0.03). 
However, there was a significant difference in substrate 
utilization, as seen in Figure 2. Data show a significant 
increase in the utilization of octanoyl carnitine (28.3 ± 
2.8 and 38.4pmol/s/mg ± 2.9, p<0.03), ADP (75.0 ± 5.6 
and 140.0pmol/s/mg ±25.1, p<0.03), glutamate (87.2 ± 
5.1 and 161.8pmol/s/mg ± 25.9, p<0.02), succinate 
(155.5 ± 27.0 and 362.8pmol/s/mg ± 47.9, p<0.01), 
oligomycin (74.8 ± 14.8 and 122.1pmol/s/mg ± 13.5, 
p<0.04) and ascorbate+TMPD (212.5 ±  24.8 and 
292.9pmol/s/mg ±  19.5, p<0.03) by the LCHP group 
compared to controls (n=6). Malate and antimycin A 
utilization were not significant (9.7 ± 1.2 and 
11.6pmol/s/mg  ± 1.34; 22.4  ± 4.3 and 20.0 pmol/s/mg 
± 3.5, respectively). The O2 flux showed an increased 
response in the LCHP group as the substrates were 
titrated as compared to controls (data not shown). 
Residual oxygen consumption (ROX) was similar in 
both groups (data not shown).  
 
 
Figure 2: Substrate utilization by the mitochondria of 
permeabilized cardiac myofibers assessed through high-
resolution respirometry. Data show a significant increase 
in the utilization of octanoyl carnitine (28.3 ± 2.8 and 
38.4pmol/s/mg ± 2.9, p<0.03), ADP (75.0 ± 5.6 and 
140.0pmol/s/mg ±25.1, p<0.03), glutamate (87.2 ± 5.1 
and 161.8pmol/s/mg ± 25.9, p<0.02), succinate (155.5 ± 
27.0 and 362.8pmol/s/mg ± 47.9, p<0.01), oligomycin 
(74.8 ± 14.8 and 122.1pmol/s/mg ± 13.5, p<0.04)  and 
ascorbate+TMPD (212.5 ±  24.8 and 292.9pmol/s/mg ±  
19.5, p<0.03) by the LCHP group compared to controls 
(n=6). Malate and antimycin A utilization were not 
significant (9.7 ± 1.2 and 11.6pmol/s/mg  ± 1.34; 22.4  ± 
4.3 and 20.0 pmol/s/mg ± 3.5, respectively). 
!
Figure 1: Immunoblotting of Complex I to Complex V 
using total OXPHOS rodent antibody cocktail from 
MitoSciences (MS604). Trends show an increase in all 5 
complexes in the LCHP diet relative to the CON diet (CI 
100%± 21.4 and 132.7%± 13.1, CII 100%± 8 and 
114.8%± 8.5, CIII 100%± 13.3 and 144.9± 20.8, CIV 
100%± 5.7 and 122.1%± 5.7 p<0.02, CV 100%± 8.4 and 















The main finding of this study is that animals assigned 
to a LCHP diet experience a drastic shift in cellular 
metabolism due to altered macronutrient distribution, 
favoring an increase in the efficiency of mitochondrial 
respiration. Taken together, the significant decrease in 
SCR and increase substrate utilization, specifically of 
ADP, indicate an increase in the efficiency of the 
mitochondria to metabolize different substrates. This 
observation was paralleled by protein expression using 





























































Figure 3:Mitochodnrial leak assessed by the difference 
between oligomycin and anitmycin a average rates of 
respiration. The data reflect a significantly increased 
mitochondrial leak in the LCHP group compared to 
controls (102.2 ± 12.1 vs 52.4 ± 16.1pmol/s/mg, 
respectively, p<0.03, n=6). !
Figure 4: Substrate control ratio (SCR) representing how 
the mitochondria handle different substrates expressed by 
dividing glutamate by succinate average rates of 
respiration. Data show a significant decrease in this ratio 
from control to the LCHP group (0.62 ± 0.08 and 0.44 ± 
0.02, respectively, p<0.05, n=6). !
Figure 5: Lipid coupling control ratio (L/P) reflecting 
the efficiency to utilize lipids yet under similar 
respiratory levels, obtained by dividing octanoyl 
carnitine by glutamate average rates of respiration. The 
data show a non-significant decrease in the L/P from the 
control to the LCHP group (0.33 ± 0.04 and 0.26 ± 0.03, 
respectively, n=6).  
!
Figure 6: The acceptor control ratio (ACR) assesses the 
relative quality of phosphorylation determined by 
dividing ADP by malate average rates of respiration. The 
data illustrate a non-significant increase in the ACR of 
the LCHP group compared to the control group  (12.0 ± 
1.4 and 8.5 ± 1.4, respectively, n=6). 
!
Figure 7: The respiratory control ratio (RCR) represents 
state 3 respiration over state 4 respiration obtained by 
diving succinate by oligomycin average rates of 
respiration. The data demonstrate a non-significant 
increase in the RCR of the control group in comparison 
to the LCHP group (2.2 ± 0.3 and 3.0 ± 0.3, respectively, 
n=6). !
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in the LCHP diet compared to the CON, with a 
significant increase in complex 4. The relatively high 
lipid content in the LCHP diet is most probably what 
impacts the mitochondria in this study rather than the 
elevated protein content, considering the two main fuel 
sources for cardiac mitochondria are carbohydrates and 
lipids. The low-carbohydrate content shifts 
mitochondrial metabolism in the heart towards its 
preferred fuel, lipids [53]. Due to the lack of ApoE in 
the CON and LCHP groups, there is a baseline increase 
in serum fatty acid levels, which is only supplemented 
with additional lipid substrate availability in the LCHP 
group due to the altered macronutrient composition. 
This may lead to an even more prominent substrate 
metabolism shift as previously mentioned, that would 
promote a greater dependency on fatty acids as the 
source of energy as seen in previous studies [54]. 
 
One possible hypothesis to explain our results would be 
that it may be in fact cytochrome c that is affected by 
the high lipid environment induced by the LCHP diet 
and not directly complex IV. The extremely basic and 
minute hemoprotein, cytochrome c, is plentiful in the 
mitochondrial intermembrane space. Its main two roles 
are transporting electrons in mitochondrial respiration 
and by being released into the cytosol from the 
mitochondria, it subsequently activates the apoptotic 
pathway [55-58]. The upregulation of complex IV may 
be a compensation for how the relatively high lipid 
content in this diet affects cytochrome c.  The second 
possible hypothesis that could contribute to better 
interpreting our results would be an upregulation in !-
oxidation responding to the elevated fatty acid 
availability. Complex I and II are less important in 
creating a proton gradient however, !-oxidation likely 
provides an extra stimulus somewhere between 
complexes I or II and complex IV promoting the extra 
surge of shuttled electrons into complex IV. 
Cytochrome c’s role would also be somewhat 
implicated in this potential explanation as well.  
 
Fatty acid metabolism has a higher oxygen cost as 
compared to carbohydrate metabolism which could 
lead to ischemic-like conditions when the mitochondria 
experience a prolonged exposure to a high lipid 
environment. Studies have shown that ischemia leads 
to a loss of cytochrome c [59]. Therefore in the LCHP 
group, there may have been a change in the presence of 
cytochrome c thus in turn affecting complex IV and the 
electron leak from the cardiac mitochondria, altering 
overall mitochondrial respiration. 
 
All in all, these speculations are in accordance with our 
findings since there was an increase in substrate 
utilization yet a decrease in SCR, implying a decrease 
in complex I. ADP being significantly increased in the 
LCHP group along with the significantly increased 
expression of complex IV could translate into an 
increased electron flow somewhere in the path towards 
complex IV, a critical component in removing 
electrons from the system. This is typically evaluated 
through effects on cytochrome c. 
 
The significant increase in mitochondrial leak despite 
no presence of an uncoupling effect, nor a change in 
the degree of coupling between oxidation and 
phosphorylation, as seen with the L/P ratio, would have 
to be further evaluated for thorough  understanding of 
this effect. In addition, variations in mitochondrial 
density should be assessed with expression of voltage-
dependent anion channel (VDAC) using 
immunoblotting. To further evaluate the hypothetical 
interpretations of our data, we could monitor changes 
when using cytochrome c during high-resolution 
respirometry titrations using the Oxygraph in 
supplemental experiments, to confirm whether it is 
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 The goal of this thesis was to better understand the role diet plays in terms of 
cardiovascular disease. In particular, my focus was on low-carbohydrate high-protein diets and 
their safety or risks involved. These diets contain negligible amounts of carbohydrates and high 
amounts of protein and fat. The lack of carbohydrates induces a shift in metabolism towards more 
fat oxidation rather than glucose utilization. This shift does not happen without consequence, and 
data from my project demonstrate that cellular and biochemical mechanisms are indeed being 
affected. Vascular smooth muscle cells demonstrated a loss in contractile proteins supporting the 
notion that the cells are undergoing a phenotype shift from contractile to synthetic, however this 
effect was not translated to a compromised functional capacity. This led us to believe that 
patients more susceptible to endothelial damage, with history of vessel occlusion, or stent 
implantation should practice a certain degree of caution when engaging on low-carbohydrate 
diets. However, in the project assessing mitochondrial function, we saw a beneficial effect 
induced by the use of fatty acids and a lipid-rich environment. The cardiac mitochondria prefer 
lipid to produce energy and demonstrated a favorable outcome, utilizing substrates and lipids 
more efficiently using lipids for ATP production.  
To further expand this project, the following suggestions are recommended: measure 
additional contractile proteins with immunoblotting for dedifferentiation evaluation, incorporate 
another experimental group 12 weeks of age to re-assess functional capacity by wire myography 
and mitochondrial functioning for an aging effect, include cytochrome c to analyze electron flow 
in cardiac mitochondria, and lastly measure reversibility of damage by adding and removing the 
diet for equal amounts of time. This will bring vital information for both clinicians and patients 
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